» Articles » PMID: 26846777

Osteoporosis Across Chronic Liver Disease

Overview
Journal Osteoporos Int
Date 2016 Feb 6
PMID 26846777
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Osteoporosis is a complication of chronic liver disease, with impact on morbidity, quality of life, and survival. The progress of medicine and the new therapies stretched the disease's natural history and improved the survival of patients with liver disease. So, it is fundamental to make better the quality of life and to prevent complications. Metabolic bone disorders are common complications of chronic liver disease (CLD). Patients with CLD have an increased risk of bone fractures, with significant impact on morbidity, quality of life, and even on survival. Bone diseases, including osteomalacia, osteoporosis, and osteopenia, are frequently observed in many types of liver disease. The pathogenesis of damage and the mechanisms of bone loss are different in relation to the specific liver disease. The relevance of these conditions induced many authors to create a new nosographic entity known as "hepatic osteodystrophy", although this term is rarely used anymore and it is now commonly referred to as osteopenia or osteoporosis associated with chronic liver disease. This review is based on the personal experiences of the authors and upon research done of the available literature on this subject matter. The authors searched the PubMed database for publications containing the term "liver disease" in combination with "bone disease", "hepatic osteodistrophy", "osteoporosis", "osteopenia", "osteomalacia", and "fractures". They selected publications from the past 10 years but did not exclude older seminal publications, especially for colestatic liver diseases. This review of literature shows that osteoporosis crosses all CLD. It is important to underline that the progress of medicine and the new therapies stretched the disease's natural history and improved the survival of patients with CLD. It is fundamental to make better the quality of life and it is mandatory to prevent complications and in particular the osteoporotic ones, especially fractures.

Citing Articles

Pharmacological considerations in pharmacotherapy of rheumatology patients with liver disease: a brief narrative review.

Shenavandeh S, Taghavi S, Nekooeian A, Moini M Reumatologia. 2024; 62(4):282-293.

PMID: 39381733 PMC: 11457314. DOI: 10.5114/reum/191791.


Bone-organ axes: bidirectional crosstalk.

Deng A, Wang F, Wang S, Zhang Y, Bai L, Su J Mil Med Res. 2024; 11(1):37.

PMID: 38867330 PMC: 11167910. DOI: 10.1186/s40779-024-00540-9.


Increased risk of fragility fractures in patients with primary biliary cholangitis.

Lim J, Kim Y, Kim S, Choi J JBMR Plus. 2024; 8(7):ziae056.

PMID: 38855796 PMC: 11162592. DOI: 10.1093/jbmrpl/ziae056.


Clinical Indicators of Bone Deterioration in Alcoholic Liver Cirrhosis and Chronic Alcohol Abuse: Looking beyond Bone Fracture Occurrence.

Stulic M, Jadzic J, Dostanic N, Zivkovic M, Stojkovic T, Aleksic J Diagnostics (Basel). 2024; 14(5).

PMID: 38472981 PMC: 10930699. DOI: 10.3390/diagnostics14050510.


Advancements in the pathogenesis of hepatic osteodystrophy and the potential therapeutic of mesenchymal stromal cells.

Xia S, Qin X, Wang J, Ren H Stem Cell Res Ther. 2023; 14(1):359.

PMID: 38087318 PMC: 10717286. DOI: 10.1186/s13287-023-03605-z.


References
1.
Gatta A, Verardo A, Di Pascoli M, Giannini S, Bolognesi M . Hepatic osteodystrophy. Clin Cases Miner Bone Metab. 2015; 11(3):185-91. PMC: 4269141. View

2.
ODonohue J, Williams R . Hormone replacement therapy in women with liver disease. Br J Obstet Gynaecol. 1997; 104(1):1-3. DOI: 10.1111/j.1471-0528.1997.tb10638.x. View

3.
Pereira R, de Carvalho J, Paula A, Zerbini C, Domiciano D, Goncalves H . Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Rev Bras Reumatol. 2012; 52(4):580-93. View

4.
Pares A, Guanabens N . Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment. Clin Liver Dis. 2008; 12(2):407-24. DOI: 10.1016/j.cld.2008.02.005. View

5.
Asano S, Suzuki A . [Assessment of the treatment of glucocorticoid-induced osteoporosis]. Clin Calcium. 2013; 23(3):401-8. DOI: CliCa1303401408. View